- The CONCLUDE study assess the hypoglycemic risk with Tresiba (qd) vs insulin glargine U300 (qd) in 1,609 patients with T2D with/out oral anti-diabetic drugs, for 36wks. maintenance period and a total treatment period of up to 88wks.
- The CONCLUDE study result: reduction in the rate of severe hypoglycemia & nocturnal symptomatic hypoglycemia (80% & 37% vs 62% & 43%) during maintenance period & total treatment period, reduction in the overall risk of hypoglycemia and significantly lower HbA1c, required insulin dose (67U vs 73U)
- Tresiba is basal insulin, providing a duration of action beyond 42hrs. with a flat and stable glucose-lowering effect, received first regulatory approval in Sept’2012 and is approved therapy in 80+ countries globally
Click here to read full press release/ article | Ref: PRNewswire | Image: Behance